mounjaro patent expiration date tirzepatide In weight loss battle, Novo and Lilly face growing offensive from licensed copies when does the patent on

It now has its own triple agonist in development and has a dual agonist of the GLP-1 and amylin hormones in phase 3 studies called amycretin

Observational data suggests that users maintaining strong protein intake and exercise routines achieve favorable fat-to-muscle loss ratios

This is of particular concern given the European Medicines Agencys (EMA) recent alert regarding a possible link between GLP-1 receptor agonists and an increased risk of suicidal ideation and behavior ( In light of these concerns, this study aims to investigate the potential association between tirzepatide use and the risk of suicide in patients with obesity

We offer nutritional guidance and ongoing support to help you build healthy habits that last a lifetime